Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice
Immunotherapy focusing on reducing the amyloid-beta (Aβ) burden is a promising treatment strategy for Alzheimer’s disease (AD). Many clinical studies on AD immunotherapies have failed due to low safety and efficacy, calling for a highly potent AD vaccine which induces sufficient antibody titer while...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/8/3/351 |
| _version_ | 1797563550302994432 |
|---|---|
| author | Dong-qun Liu Shuai Lu Lun Zhang Ya-ru Huang Mei Ji Xiao-ying Sun Xiao-ge Liu Rui-tian Liu |
| author_facet | Dong-qun Liu Shuai Lu Lun Zhang Ya-ru Huang Mei Ji Xiao-ying Sun Xiao-ge Liu Rui-tian Liu |
| author_sort | Dong-qun Liu |
| collection | DOAJ |
| description | Immunotherapy focusing on reducing the amyloid-beta (Aβ) burden is a promising treatment strategy for Alzheimer’s disease (AD). Many clinical studies on AD immunotherapies have failed due to low safety and efficacy, calling for a highly potent AD vaccine which induces sufficient antibody titer while avoiding side effects. Here, we designed a yeast-based vaccine Y-5A15 comprising five copies of Aβ1-15 displayed on the surface of yeast cell wall, and we subcutaneously immunized APP/PS1 mice three times. Our results demonstrated that the Y-5A15 remarkably enhanced the Aβ epitope immunogenicity and elicited high antibody titers against Aβ in AD mice. Importantly, Y-5A15 vaccination successfully reduced Aβ levels, plaque burden and glial activation, rescued synaptic deficits and significantly ameliorated memory and cognitive decline in APP/PS1 transgenic mice, suggesting that the yeast-based Aβ epitope vaccine has a promising potency for the treatment of AD. |
| first_indexed | 2024-03-10T18:44:13Z |
| format | Article |
| id | doaj.art-13b7b46a031c4de59d1e6b3c2214995e |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T18:44:13Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-13b7b46a031c4de59d1e6b3c2214995e2023-11-20T05:34:59ZengMDPI AGVaccines2076-393X2020-07-018335110.3390/vaccines8030351Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic MiceDong-qun Liu0Shuai Lu1Lun Zhang2Ya-ru Huang3Mei Ji4Xiao-ying Sun5Xiao-ge Liu6Rui-tian Liu7National Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaNational Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaNational Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaNational Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaNational Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaNational Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaNational Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaNational Key Laboratory of Biochemical Engineering, Institute of Process Engineering, Chinese Academy of Sciences, Beijing 100190, ChinaImmunotherapy focusing on reducing the amyloid-beta (Aβ) burden is a promising treatment strategy for Alzheimer’s disease (AD). Many clinical studies on AD immunotherapies have failed due to low safety and efficacy, calling for a highly potent AD vaccine which induces sufficient antibody titer while avoiding side effects. Here, we designed a yeast-based vaccine Y-5A15 comprising five copies of Aβ1-15 displayed on the surface of yeast cell wall, and we subcutaneously immunized APP/PS1 mice three times. Our results demonstrated that the Y-5A15 remarkably enhanced the Aβ epitope immunogenicity and elicited high antibody titers against Aβ in AD mice. Importantly, Y-5A15 vaccination successfully reduced Aβ levels, plaque burden and glial activation, rescued synaptic deficits and significantly ameliorated memory and cognitive decline in APP/PS1 transgenic mice, suggesting that the yeast-based Aβ epitope vaccine has a promising potency for the treatment of AD.https://www.mdpi.com/2076-393X/8/3/351Alzheimer’s diseasebeta-amyloidactive immunotherapyyeastvaccine |
| spellingShingle | Dong-qun Liu Shuai Lu Lun Zhang Ya-ru Huang Mei Ji Xiao-ying Sun Xiao-ge Liu Rui-tian Liu Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice Vaccines Alzheimer’s disease beta-amyloid active immunotherapy yeast vaccine |
| title | Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice |
| title_full | Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice |
| title_fullStr | Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice |
| title_full_unstemmed | Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice |
| title_short | Yeast-Based Aβ1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice |
| title_sort | yeast based aβ1 15 vaccine elicits strong immunogenicity and attenuates neuropathology and cognitive deficits in alzheimer s disease transgenic mice |
| topic | Alzheimer’s disease beta-amyloid active immunotherapy yeast vaccine |
| url | https://www.mdpi.com/2076-393X/8/3/351 |
| work_keys_str_mv | AT dongqunliu yeastbasedab115vaccineelicitsstrongimmunogenicityandattenuatesneuropathologyandcognitivedeficitsinalzheimersdiseasetransgenicmice AT shuailu yeastbasedab115vaccineelicitsstrongimmunogenicityandattenuatesneuropathologyandcognitivedeficitsinalzheimersdiseasetransgenicmice AT lunzhang yeastbasedab115vaccineelicitsstrongimmunogenicityandattenuatesneuropathologyandcognitivedeficitsinalzheimersdiseasetransgenicmice AT yaruhuang yeastbasedab115vaccineelicitsstrongimmunogenicityandattenuatesneuropathologyandcognitivedeficitsinalzheimersdiseasetransgenicmice AT meiji yeastbasedab115vaccineelicitsstrongimmunogenicityandattenuatesneuropathologyandcognitivedeficitsinalzheimersdiseasetransgenicmice AT xiaoyingsun yeastbasedab115vaccineelicitsstrongimmunogenicityandattenuatesneuropathologyandcognitivedeficitsinalzheimersdiseasetransgenicmice AT xiaogeliu yeastbasedab115vaccineelicitsstrongimmunogenicityandattenuatesneuropathologyandcognitivedeficitsinalzheimersdiseasetransgenicmice AT ruitianliu yeastbasedab115vaccineelicitsstrongimmunogenicityandattenuatesneuropathologyandcognitivedeficitsinalzheimersdiseasetransgenicmice |